The advancements in Biologics are not just rapidly realigning perceptions regarding medical concepts but also opening up a land mine of opportunities in the area of Bio-Pharmaceutical drugs. On one hand is the clear advantage that Bio-pharmaceutical drugs can address - the hitherto unmanageable clinical needs by conventional therapeutics and therefore worth a premium. On the other is the undeniable connection between investments in nanotechnologies and the hunt for new molecules plays a pivotal for the future of Biologics and subsequently to the lifesciences industry itself.

Consider this:

• The fact that annual global sales of Biologics has leap-frogged from $ 30 billion (1999) to $ 139 billion (2010) is evident of the NEXT investment opportunities in lifesciences.
• Share of Biologics in the global Bio-Pharmaceuticals market is projected to rise to 28.9% in 2015, from a base of 4.5% in 1990.
• In the coming decade, Biologics will dominate the global Bio-Pharmaceutical drugs market, since 8 of the top 10 blockbusters of 2014-15 are to be Biologics or biotechnological products.
• In terms of spends, the share of Biologics in the Global Pharmaceutical market is projected to rise to 17% in 2016 from 14% in 2006 as important clinical advances continue to emerge from research, and patients around the world are treated.